Buparlisib plus paclitaxel did not improve overall survival compared to paclitaxel alone in PD-1/PD-L1-pretreated recurrent/metastatic HNSCC patients. The combination showed a higher overall response ...
Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.
“We are excited to see this strong survival benefit for head and neck cancer patients with such cold tumors. Combining these two complementary immunotherapies has led to a 7-fold increase in response ...
PDS0101 and pembrolizumab combination achieved a median overall survival of 39.3 months in HPV16-positive head and neck cancer patients with a CPS of at least 1. The VERSATILE-002 trial showed ...
Please provide your email address to receive an email when new articles are posted on . Neoadjuvant combination immunotherapy regimens produced higher pathologic response rates than monotherapy in a ...
CHICAGO — In another noteworthy outcome for a PD-1 immunotherapy; nearly one-quarter of patients with advanced head and neck cancer responded to treatment with pembrolizumab (Keytruda, Merck), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback